Insider buying last 90 days
No open-market insider purchases were filed for ABVX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ABVX insider filing, plotted on the chart in Gekko.Open ABVX in Gekko
Gekko Brief
AI summaryAbivax shares this week were driven by positive Phase 3 trial data for lead drug obefazimod in ulcerative colitis, which prompted Goldman Sachs to initiate coverage with a "Buy" rating and a $155 target, alongside ratings from Truist and Wedbush. The company also extended its cash runway into Q4 2029 following a $920 million public offering, and announced leadership changes. Coverage also noted a deepening net loss of €117.433 million in Q2 2026, even as revenue increased, and some commentary flagged weak near and mid-term sentiment despite a strong long-term outlook.
The stock closed at $96.85, up 6.4%, but remains below both its 50-day average of $117.04 and 200-day average of $118.43, with the 50-day below the 200-day. Over the past month the shares are down 15.3%, though the one-year return stands at 18.1%. The GekkoIndex reads 68.7, placing the stock in the Accumulation zone, while price sits 22.2% below Gekko Fair Value of $124.48.
Over the next 20 trading days, the next earnings date falls on 21 December 2026, 83 days away and outside a typical holding window. In the last 30 days there have been 2 unusual options signals, with put premium of $3,926,269 against call premium of $839,545. Analyst coverage shows 8 buy ratings and 1 hold among 9 firms, with a consensus target of $164 and consensus upside of 69.3%. The gap to Gekko Fair Value bears watching given the stock's typical 20-day move of 10.8%.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Abivax price vs fair value
Close $96.85200-day averageGekko Fair Value $124.48
Abivax quick facts
- Market cap
- $7.11B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$6.11
- Revenue, TTM
- $4.67M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- -0.25
- Volume
- 1.68M avg 1.35M
- 1-year return
- +18.1%
- Typical daily move
- ±5.2%
- Typical 20-day move
- ±10.8%
- 50-day average
- $117.04
- 200-day average
- $118.43
- Next earnings
- Dec 21
- Shares outstanding
- 87.25M
Abivax swing-trade checklist
Abivax scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $96.85 is below the 50-day ($117.04) and 200-day ($118.43) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
68.7, Accumulation
Reading 68.7 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
22.2% below
Price is 22.2% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyheadwind
Leans bearish
Last 30 days: 2 unusual options signals.
See smart money - Earnings risksupportive
Reports in 83 days
Next report Dec 21, 2026, 83 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Abivax stock chart and price history
Abivax closed at $96.85 on Sep 28, 2026, +18.1% over the past year, inside a 52-week range of $69.81 to $148.83.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −15.3%
- 3 months
- +0.7%
- 6 months
- −5.5%
- 1 year
- +18.1%
The full ABVX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ABVX in Gekko
Follow Abivax through every session
Put ABVX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ABVX in GekkoFree for 7 days. No credit card required.
About Abivax
Abivax works on developing drug candidates aimed at inflammatory, infectious, and oncological conditions. Its most advanced program centers on a compound called ABX464, which has been studied for ulcerative colitis, Crohn's Disease, and COVID-19, with additional testing in rheumatoid arthritis and earlier work showing viral remission results in HIV patients. The company is also progressing a second candidate, ABX 196, designed to stimulate immune response, in trials targeting hepatocellular cancer.
Beyond its core pipeline, Abivax runs research programs directed at Dengue fever, influenza, and respiratory syncytial virus. Its work is supported by license arrangements with French research institutions, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie, connecting its drug development efforts to established scientific bodies.
Abivax was established in 2013 and is headquartered in Paris, France. Its shares trade under the ticker ABVX.
- Sector
- Health technology
- Website
- abivax.com
Abivax GekkoIndex: the smart money zone
Abivax’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 68.7, in the Accumulation zone, up 1.4 points over five sessions.
68.7Accumulation
Up 1.4 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 42 | +2.2% | +2.8% | ||
| Accumulation (current zone) | 239 | Not available | |||
| Neutral | 295 | Not available | |||
| Distribution | 44 | Not available | |||
| Selling | 5 | Too few readings yet | |||
Average ABVX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the ABVX price, zone by zone.Track ABVX in Gekko
Is Abivax stock overvalued? Gekko Fair Value
Abivax trades 22.2% below Gekko Fair Value of $124.48, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Abivax shares are worth, recalculated every trading day.
$124.48
Gekko Fair Value, Sep 29, 2026
22.2% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open ABVX in Gekko
Abivax insider and Congress trading
No open-market insider purchases were filed for Abivax, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ABVX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ABVX, plotted on the chart in Gekko.Open ABVX in Gekko
Unusual options activity last 30 days
2signals, 18% of the flagged premium in calls.
Latest: Bullish flow on Sep 24, $1.51M in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
3of the funds Gekko tracks hold ABVX.
1added1opened1trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Abivax earnings: next date and track record
Abivax reports on Dec 21, 2026 (83 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Dec 21, 2026
83 days away
- EPS estimate
- −$1.27
- Revenue estimate
- $794K
4 of 8reports beat the EPS estimate
±8.2%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Sep 21, 2026 | −$1.71 est −$1.03 | $1.37M est $799K | −6.4% |
| May 22, 2026 | −$0.71 est −$0.81 | $1.51M est $401K | +1.9% |
| Mar 23, 2026 | −$1.18 est −$1.04 | $515K est $1.80M | −8.5% |
| Dec 15, 2025 | −$2.47 est −$0.79 | $2.40M est $1.35M | −11.6% |
| Sep 8, 2025 | −$0.89 est −$0.95 | $1.33M est $1.35M | +1.4% |
| Jun 2, 2025 | −$0.95 est −$0.76 | $1.16M est $3.35M | +28.6% |
| Mar 24, 2025 | −$0.81 est −$1.29 | $6.37M est $2.83M | −0.5% |
| Nov 14, 2024 | −$0.70 est −$0.70 | — est $3.59M | −6.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Abivax stock forecast and analyst price targets
Analysts’ average 12-month price target for Abivax is $164.00, +69.3% from the last close, from 9 firms rating the stock in the last 90 days.
$164.00consensus 12-month target, +69.3% from the last close
Now $96.85Avg $164.00
Low $118High $180
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 28 | Morgan Stanley | $180 | +85.9% |
| Sep 22 | Barclays | $148 | +52.8% |
| Sep 22 | LifeSci Capital | $168 | +73.5% |
| Sep 22 | Truist Financial | $151 | +55.9% |
| Sep 22 | Wedbush | $118 | +21.8% |
±5.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Abivax market cap and key statistics
Abivax’s market cap is $7.11B and revenue of $4.67M over the last twelve months.
Valuation
- Market cap
- $7.11B
- EPS, TTM
- −$6.11
- Gekko Fair Value
- $124.48
Trading
- Volume
- 1.68M
- Avg volume, 20 days
- 1.35M
- 52-week high
- $148.83
- 52-week low
- $69.81
- Shares outstanding
- 87.25M
Financials
- Revenue, TTM
- $4.67M
- Profit margin
- 0%
- Return on equity
- -252.3%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- -0.25
- Typical daily move
- ±5.2%
- Typical 20-day move
- ±10.8%
Abivax stock news this week
Coverage of Abivax this week reads positive: 8 positive, 1 neutral and 3 negative headlines.
- ABVX Stock Draws Bullish Targets As Obefazimod Momentum BuildsStocksToTrade, Sep 28
- ABIVAX Société Anonyme (ENXTPA:ABVX) Following New Leadership Hires And Wider Losses Looks UndervaluedSimply Wall Street, Sep 28
- How Abivax Sa (ABVX) Affects Rotational Strategy TimingStock Traders Daily, Sep 25
- Bavarian Nordic names new CEO; Abivax and ProQR add key leadersEuropean Biotechnology Magazine, Sep 25
- Abivax: Priced Right Ahead Of 2 Make-Or-Break CatalystsSeeking Alpha, Sep 23
- Abivax Extends Cash Runway Into Q4 2029 Following $920 Million Offering And Announces Leadership ChangesPulse 2.0, Sep 23
Abivax stock FAQ
What is Abivax’s market cap?
Abivax’s market cap is $7.11B at the Sep 28, 2026 close of $96.85, with 87.25M shares outstanding.
What is the Abivax stock forecast?
The consensus analyst 12-month price target for Abivax is $164.00, +69.3% from the last close. Of the 9 firms that rated the stock in the last 90 days, 8 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Abivax stock overvalued or undervalued?
On Gekko’s estimate Abivax is undervalued: the Sep 28, 2026 close of $96.85 is 22.2% below Gekko Fair Value of $124.48. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Abivax report earnings next?
Abivax is expected to report on Dec 21, 2026 (83 days away). Analysts expect earnings of −$1.27 per share on revenue of $794K. Abivax beat the earnings estimate in 4 of its last 8 reports, moving 8.2% on average across the report.
What is Abivax’s 52-week high and low?
Abivax’s 52-week high is $148.83 and its 52-week low is $69.81; it closed at $96.85 on Sep 28, 2026, +18.1% over the past year.
Is Abivax stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk) and 2 as headwinds (trend and smart money). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Abivax?
Gekko flagged 2 unusual options signals in Abivax over the last 30 days, with $840K of flagged premium in calls and $3.93M in puts. The latest, bullish flow, was on Sep 24, 2026 with $1.51M in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Abivax the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.